Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis.
作者信息
Saeed Anzel, Rai Kuldeep Dalpat, Saeed Muzammil
机构信息
Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Department of Medicine, Karachi Medical and Dental College, Karachi Metropolitan University, Karachi, Pakistan.
出版信息
Liver Res. 2024 Jul 14;8(3):193-194. doi: 10.1016/j.livres.2024.07.002. eCollection 2024 Sep.
Abstract
摘要
相似文献
1
Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis.瑞美替隆：代谢功能障碍相关脂肪性肝炎的突破性治疗方法。
Liver Res. 2024 Jul 14;8(3):193-194. doi: 10.1016/j.livres.2024.07.002. eCollection 2024 Sep.
2
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential.Resmetirom用于治疗代谢功能障碍相关脂肪性肝炎（MASH）：当前证据与治疗潜力的全面综述
Cureus. 2024 Nov 29;16(11):e74772. doi: 10.7759/cureus.74772. eCollection 2024 Nov.
3
Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).瑞美替隆：首个获美国食品药品监督管理局批准用于治疗非酒精性脂肪性肝炎（NASH）的药物。
Ann Pharmacother. 2025 Feb;59(2):162-173. doi: 10.1177/10600280241259528. Epub 2024 Jun 17.
4
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals.雷西莫特罗姆与代谢相关脂肪性肝炎：全球医疗保健专业人士对多学科管理的观点。
Curr Obes Rep. 2024 Dec;13(4):818-830. doi: 10.1007/s13679-024-00582-z. Epub 2024 Aug 7.
5
Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systematic review and meta-analysis.瑞美替隆治疗代谢功能障碍相关脂肪性肝炎（MASH）的安全性和有效性：一项系统评价和荟萃分析
Eur J Gastroenterol Hepatol. 2025 Apr 1;37(4):395-402. doi: 10.1097/MEG.0000000000002901. Epub 2024 Dec 3.
6
The first MASH drug therapy on the horizon: Current perspectives of resmetirom.地平线上的首个 MASH 药物治疗：雷美替胺的当前观点。
Liver Int. 2024 Jul;44(7):1526-1536. doi: 10.1111/liv.15930. Epub 2024 Apr 5.
7
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.在一项为期52周、双盲、随机、安慰剂对照的III期研究中，对患有代谢功能障碍相关脂肪性肝炎（MASH）和纤维化的患者进行与健康相关的生活质量（HRQL）评估，该研究使用resmetirom（MGL-3196）。
Hepatology. 2025 Apr 1;81(4):1318-1327. doi: 10.1097/HEP.0000000000001084. Epub 2024 Sep 6.
8
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.选择性甲状腺激素受体-β激动剂 Resmetirom 治疗代谢功能障碍相关脂肪性肝病（MASLD）的疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2024 Aug 26;14(1):19790. doi: 10.1038/s41598-024-70242-8.
9
Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting.在真实临床环境中使用resmetirom治疗伴有纤维化的代谢功能障碍相关脂肪性肝炎的早期经验。
Hepatol Commun. 2025 Apr 3;9(4). doi: 10.1097/HC9.0000000000000670. eCollection 2025 Apr 1.
10
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom.非酒精性脂肪性肝炎的药物研发管线：从瑞美鲁肽的成功案例中能学到什么。
Curr Issues Mol Biol. 2025 Feb 27;47(3):154. doi: 10.3390/cimb47030154.
引用本文的文献
1
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD.非酒精性脂肪性肝炎的免疫致病机制及免疫调节疗法
Cell Mol Immunol. 2025 Jun 10. doi: 10.1038/s41423-025-01307-5.
2
Unlocking the potential of THR-β agonist therapies: resmetirom's chemistry, biology, and patent insights.释放THR-β激动剂疗法的潜力：雷司美托的化学、生物学及专利见解
Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9703-9720. doi: 10.1007/s00210-025-03880-y. Epub 2025 Mar 11.
本文引用的文献
1
Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.Resmetirom 作为一种肝脏靶向、甲状腺激素受体β选择性激动剂，在治疗非酒精性脂肪性肝炎中的作用：系统评价和荟萃分析。
Endocr Pract. 2024 Jul;30(7):631-638. doi: 10.1016/j.eprac.2024.04.016. Epub 2024 May 1.
2
The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.熊去氧胆酸治疗非酒精性脂肪性肝炎患者的疗效和安全性：一项系统评价和随机对照试验的荟萃分析。
Medicine (Baltimore). 2024 Feb 16;103(7):e37271. doi: 10.1097/MD.0000000000037271.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的病因、发病机制及治疗
N Engl J Med. 2017 Nov 23;377(21):2063-2072. doi: 10.1056/NEJMra1503519.
5
Pharmacotherapy for NASH: Current and emerging.非酒精性脂肪性肝炎的药物治疗：现状与进展。
J Hepatol. 2018 Feb;68(2):362-375. doi: 10.1016/j.jhep.2017.10.015. Epub 2017 Nov 6.
6
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
7
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.非酒精性脂肪性肝病中纤维化阶段导致的死亡风险增加：系统评价与荟萃分析
Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.
8
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.肝纤维化而非其他组织学特征与非酒精性脂肪性肝病患者的长期预后相关。
Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.
Zotero 插件